Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

Clara Grazia Chisari, Luigi Maria Grimaldi, Giuseppe Salemi, Paolo Ragonese, Pietro Iaffaldano, Simona Bonavita, Maddalena Sparaco, Marco Rovaris, Alessia D'Arma, Alessandra Lugaresi, Maria Teresa Ferrò, Paola Grossi, Alessia DI Sapio, Eleonora Cocco, Franco Granella, Erica Curti, Vito Lepore, Maria Trojano, Francesco Patti

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population. Materials and methods This retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the 'Italian MS Register'. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions on average from 28 to 32 days (median 30) and extended interval dosing (EID) including patients who have been infused with interval between 33 and 49 days (median 43). Clinical data were assessed at baseline (before starting NTZ), after 12 (T1) and 24 months (T2) of treatment. Results Out of 5231 patients with RR-MS screened, 2092 (mean age 43.2±12.0, 60.6% women) were enrolled. A total of 1254 (59.9%) received NTZ according to SID, and 838 (40.1%) according to EID. At 12 and 24 months, no differences in terms of annualised relapse rate and disability status were found between the two groups. Progression index and confirmed disability worsening were similar between the two groups. Discussion The use of NTZ with an extended interval schedule showed similar effectiveness compared with SID. Unchanged clinical efficacy of EID schedule may raise the question of a possible advantage in terms of tolerability and safety.

Original languageEnglish
Pages (from-to)1297-1303
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume91
Issue number12
DOIs
Publication statusPublished - Dec 1 2020

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this